FDA approval sought on new dry eye drops

Bausch + Lomb and biopharmaceutical company Novaliq have sought approval from the US Food and Drug Administration (FDA) on a new drug for dry eye disease, related to Meibomian gland dysfunction.

The drug application, NOV03 (perfluorohexyloctane), is an water-free, single-component preservative-free eye drop.

Christian Roesky, CEO at Novaliq, said: 'We are working hand-in-hand with Bausch + Lomb to bring this novel treatment option, if approved, to the optometric and ophthalmic community so they can help address the needs of patients with dry eye disease associated with Meibomian gland dysfunction.

'This New Drug Application submission is a critical milestone and the first drug submission of a water-free therapy. We are excited to unfold the full potential of NOV03 by bringing this novel drug option for this condition to the United States.'